Rani Therapeutics Holdings Inc - Ordinary Shares Class A

Rani Therapeutics Holdings Inc - Ordinary Shares Class A

RANI - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$104.74M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Rani Therapeutics Holdings Inc - Ordinary Shares Class ARani Therapeutics Holdings Inc - Ordinary Shares Class A-2.8--96%-0.2
$0.17

Current Fair Value

67.9% downside

Overvalued by 67.9% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$104.74 Million
Enterprise Value$107.68 Million
Earnings per Share$-0.45
Beta0.68
Outstanding Shares199,006,000

Return

Return on Equity-95.54%ROE
Return on Assets-61.79%
Return on Invested Capital-80.64%

Valuation & Multiples

P/E Ratio-2.78P/E Ratio
PEG-6.5PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue31.53
Enterprise Value to EBIT-3.08
Enterprise Value to Net Income-4
Total Debt to Enterprise0.06
Debt to Equity0.19Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 10, 2026
EPS
-$0.04
Est. -$0.05
Revenue
$1.71 M
Est. $1.28 M

Next Earnings Call

Expected Date
March 25, 2027
EPS Estimate
-$0.06
Consensus analyst estimate
Revenue Estimate
$1.60 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.0000▼ 78.39%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.77%▼ 23.63%
Total Invested$1.13M▼ 96.74%
Investors Holding13▼ 57.00%

About Rani Therapeutics Holdings Inc

2,021 employees

Rani Therapeutics Holdings Insider Information FAQ

Stockcircle tracks 3 top investors with a current 13F position in Rani Therapeutics Holdings. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 1 top investor increased or opened positions among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 2 open-market insider purchases for Rani Therapeutics Holdings in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.